Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
- 주제(키워드) KEY WORDS , Schizophrenia , Antipsychotics , Paliperidone palmitate , Clinical global impression , Personal and social performance
- 주제(기타) Neurosciences; Pharmacology & Pharmacy
- 설명문(일반) [Oh, Jihoon; Oh, Jihye; Kim, Jung-Jin] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Psychiat, Seoul, South Korea; [Kim, Dong Wook] Maumpyeonhan Mental Hlth Clin, Bucheon, South Korea; [Youn, HyunChul] Soonchunhyang Univ, Bucheon Hosp, Dept Psychiat, Bucheon, South Korea; [Kim, Sae-Hoon] Yangsan Hosp, Yangsan, South Korea; [Kim, Soo In] Ewha Womans Univ, Coll Med, Dept Psychiat, Seoul, South Korea; [Chung, In Won] St Andrews Hosp, Inst Spiritual & Mental Hlth, Icheon, South Korea; [Wang, Kuan Shu] Maryknoll Med Ctr, Dept Psychiat, Busan, South Korea; [Koh, Min Jung] Seoul Natl Univ Hosp, Dept Neuropsychiat, Seoul, South Korea; [Paik, Jong -Woo] Kyung Hee Univ, Kyung Hee Univ Hosp, Coll Med, Dept Psychiat, Seoul, South Korea; [Koh, Min Jung; Lee, Yoosun; Choi, Seok Young] Janssen Korea, Med Affairs, Seoul, South Korea; [Kim, Jung-Jin] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Psychiat, Seoul St,222 Banpo Daero, Seoul 06591, South Korea
- 등재 SCIE, SCOPUS, KCI등재
- 발행기관 KOREAN COLL NEUROPSYCHOPHARMACOLOGY
- 발행년도 2023
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000204310
- 본문언어 영어
- Published As https://doi.org/10.9758/cpn.2023.21.1.126pISSN1738-1088/eISSN2093-4327
초록/요약
Objective: To investigate the effects of long-acting injectable 3-monthly paliperidone palmitate on the clinical and social functioning of patients with schizophrenia. Methods: This study enrolled patients with schizophrenia receiving long-acting injectable 1-monthly paliperidone palmi-tate for at least 4 months and who subsequently received 3-monthly paliperidone palmitate. Accordingly, 418 patients were followed up for 24 weeks. Their clinical symptoms and social functioning were measured using the Clinical Global Impression-Severity of Illness and Personal and Social Performance scales. Results: The Personal and Social Performance total score was significantly higher after 3-monthly paliperidone palmitate treatment than at baseline (baseline vs. week 24: 54.3 +/- 18.0 vs. 61.0 +/- 14.5 [mean +/- standard deviation]; p < 0.001; Wilcoxon signed-rank test); the proportion of patients in the mildly ill group (scores 71-100) also increased significantly (baseline vs. week 24: 16.5% vs. 20.6%; p < 0.001; McNemar-Bowker test). The mean Clinical Global Impression-Severity of Illness score decreased significantly (baseline vs. week 24: 3.7 +/- 1.0 vs. 3.4 +/- 0.9; p < 0.001; Wilcoxon signed-rank test), as did the proportion of patients in the severely ill group (baseline vs. week 24: 4.1% vs. 2.1%; p < 0.001; McNemar-Bowker test). Conclusion: Continuous 3-monthly paliperidone palmitate treatment significantly enhances the personal and social per-formance of patients with schizophrenia and reduces the proportion of those with severe illness. These findings suggest that long-acting injectable antipsychotic administration at intervals longer than 1 month might improve the social func-tioning of and promote return to activities of daily living in patients with schizophrenia.
more